natgillin/translations-raw huggingface dataset:
Compound as claimed in claims 9 or 10, wherein R1 is selected from methyl, cyclopropyl and trifluoromethyl and/or R2 is selected from methoxyphenyl, methylphenyl, 1-benzothiophen-3-yl, 1-ethylpropyl, 1-methyl-1 H -pyrrol-2-yl, 2-methylethyl, pyridin-3yl, cyclopentyl and cyclohexyl and/or R3 is selected from: C2-C4 alkyl; 4yl-butan-2one; - CH2-Z wherein Z is dimethylamino, cyclopentyl, benzotriazol-1-yl, isoindol-1, 3(2H)-dione-2-yl, imidazol-4-yl, 1,2,3-triazol-1-yl, indol-1-yl, furan-2-yl, or phenyl, unsubstituted or substituted with one or more groups selected from F, methyl, methoxy and dimethylamino; C3-C6 cycloalkyl unsubstituted or substituted with one or more groups selected from F and methyl; 2-methyl-1,3-oxazol-4-yl; phenyl unsubstituted or substituted with one or more groups selected from methyl, hydroxy, F and nitro; dimethylamino. 
Spoj u skladu s patentnim zahtjevima 9 ili 10, naznačen time što se R1 bira između metila, ciklopropila i trifluormetila i/ili R2 se bira između metoksifenila, metilfenila, 1-benzotiofen-3-ila, 1-etilpropila, 1-metil-1H-pirol-2-ila, 2-metiletila, piridin-3-ila, ciklopentila i cikloheksila i/ili R3 se bira između: C2-C4 alkila; 4-ilbutan-2-ona; -CH2-Z, gdje je Z dimetilamino, ciklopentil, benzotriazol-1-il, izoindol-1, 3(2H)-dion-2-il, imidazol-4-il, 1,2,3-triazol-1-il, indol-1-il, furan-2-il, ili fenil, koji je nesupstituiran ili je supstituiran s jednom ili više skupina, koje se bira između F, metila, metoksi i dimetilamino; C3-C6 cikloalkil, koji je nesupstituiran ili je supstituiran s jednom ili više skupina, koje se bira između F i metila; 2-metil-1,3-oksazol-4-il; fenil, koji je nesupstituiran ili je supstituiran s jednom ili više skupina, koje se bira između metila, hidroksi, F i nitro; dimetilamino.
The composite structure according to claim 1 wherein the composite structure further comprises woven and non-woven webbing reinforcement as one or more layers. 
Kompozitna struktura sukladno zahtjevu 1, naznačen time, da se nadalje sastoji od tkanog i netkanog mrežnog pojačanja u jednom ili više slojeva.
Use of the inorganic coating according to claim 13 to 15 on a particulate ammonium nitrate-based fertilizer, for the incorporation of macronutrients, micronutrients or a combination thereof, wherein the liquid concentrated mineral acid and the solid mineral alkaline in powder form are the source of any one of the macronutrients and the micronutrients. 
Upotreba anorganskog premaza u skladu s patentnim zahtjevima 13 do 15 na praškastom umjetnom gnojivu na HR P20180796 T1 bazi amonijeva nitrata, naznačen time, da se koristi za ugradnju makronutrijenata, mikronutrijenata ili njihovu kombinaciju, pri čemu su tekuća koncentrirana mineralna kiselina i kruta mineralna lužina u praškastom obliku izvor bilo kojeg od makronutrijenata i mikronutrijenata.
An embodiment of the present invention is a compound of selective peroxisome proliferator activated receptor modulator (SPPARM) or a compound having the PPARY partial agonist activity, which has a structural formula 1, or a pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein: R1 and R2 are each independently: methyl or ethyl. 
Bit izuma Izvedba ovog izuma je spoj koji je selektivni modulator receptora aktiviranog peroksisomskim proliferatorom (SPPARM) ili spoj s aktivnošću parcijalnog agonista PPARy, strukturne formule 1, iH
The invention further provides the use of (A) as herein before defined or (B) as herein before defined in the preparation of a medicament for combination therapy by simultaneous, sequential, or separate administration of (A) and (B) in the treatment of respiratory diseases. 
Izum nadalje daje uporabu od (A) kako je ovdje prije definirano ili (B) kako je ovdje prije definirano, u pripremanju lijeka za kombiniranu terapiju kod istodobnog davanja, davanja jednog za drugim, ili zasebnog davanja (A) i (B) kod liječenja respiratornih bolesti.
the filtering means adds a value obtained by inverse-quantizing the offset by using a parameter included in the offset attributes to the pixel value of each pixel. The image filtering device according to Claim 3, wherein the filtering means inverse-quantizes the decoded offset by performing bitwise left shift on the decoded offset by an amount equal to a shift value obtained by subtracting the offset bit depth from the bit depth of the pixel values. 
određivanje dubine offset bita u skladu s dubinom bita za vrijednosti piksela radi daljnjeg određivanja raspona vrijednosti offset-a i određivanje vrijednosti pomaka upućivanjem na vrstu offset-a koja navodi informacije uključene u kodirane podatke, pri čemu je maksimalna duljina bita koja predstavlja raspon vrijednosti offset-a jednaka dubini offset bita-K, a vrijednost K jednaka je 4;
A formulation comprising an aqueous carrier, a buffer and a polypeptide with SEQ ID NO: 1, said formulation being formulated for administration to a human subject, wherein the polypeptide has a concentration of at least 30 mg/ml, wherein the buffer is disodium hydrogen phosphate (Na2HPO4), pH 7.0 at a concentration of 10mM. 
Formulacija koja sadrži vodeni nosač koji ima pH od 5.5 do 8.0 i polipeptid koji sadrži jednu ili više pojedinačnih varijabilnih domena u koncentraciji od 1 mg/mL do 200 mg/mL, navedena formulacija formulirana je za davanje ljudskom subjektu i navedena formulacija nadalje sadrži histidinski pufer u koncentraciji od 10 mM do 100 mM, pH 6.0-6.5; pri čemu navedena formulacija ima koncentraciju anorganske soli od 150 mM ili nižu, pri čemu je polipeptid odabran od jedne od SEQ ID NO: 1 do 6 i pri čemu pH formulacije iznosi između 6.2 i 7.5.
obtaining the PLP corresponding to the identifier of the PLP and the identifier of the transmission system included in the NIT; and obtaining a transport stream, TS, to which the PLP is mapped, wherein a transmission delivery system descriptor including the identifier of the PLP, the identifier of the transmission system, and an active Orthogonal Frequency Division Multiplexing, OFDM, symbol duration field in a TS loop of the NIT maps transport streams to PLPs in data slices of the transmission systems. 
dobivanje PLP-a koji odgovara identifikatoru PLP-a i identifikatoru C2 sustava uključenog u NIT; i dobivanje prijenosnog toka (transport stream, TS) prema kojem je PLP mapiran, gdje deskriptor C2 dostavnog sustava, uključujući identifikator PLP-a i identifikator C2 sustava u TS petlji NIT mapa, prenosi tokove do PLP-ova u podatkovnim komadima C2 sustava.
The method of claim 1, wherein the ratio of the first lipid nanoparticle to the second lipid nanoparticle in the pharmaceutical composition is about 1:1 or about 2:1 or about 3:1 or about 4:1. 
Farmaceutski pripravak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da omjer prve lipidne nanočestice i druge lipidne nanočestice u farmaceutskom pripravku iznosi približno 1:1, približno 2:1, približno 3:1 ili približno 4:1.
A compound of Formula (A): or a pharmaceutically acceptable salt, or stereoisomer thereof; wherein 
Spoj, naznačen time, da ima formulu (A): ili njegova farmaceutski prihvatljiva sol, ili njegov stereoizomer; pri čemu Prsten A je fenil ili piridil; X je –C(O)- ili –S(O)2-;
The method of item 66, wherein the second therapeutic agent is selected from the group consisting of: a TNF inhibitor, an IL-1 inhibitor, an IL-5 inhibitor, an IL-8 inhibitor, an IgE inhibitor, a leukotriene inhibitor, a corticosteroid, a methylxanthine, an NSAID, nedocromil sodium, cromolyn sodium, a long-acting beta2 agonist, an anti-fungal agent, and a combination thereof. 
HR P20181963 T1 čemu je, poželjno, drugo terapijsko sredstvo odabrano iz skupine koja sadrži: inhibitor TNF, inhibitor IL-I, inhibitor IL-5, inhibitor IL-8, inhibitor IgE, inhibitor leukotriena, kortikosteroid, metilksantin, NSAID, nedokromil natrij, kromolin natrij, dugo djelujući beta2 agonist, antigljivično sredstvo, te njihovu kombinaciju.
reaction of compound 2 with hexachloroacetone in dichloromethane added with triphenylphosphine at a temperature of 0-5°C followed by heating to 10-15°C, to yield 7a-chloro-5,6B-epoxy-15B,16B-methylen-3B-pivaloyloxy-5B-androstan-17-one 3: 
reakcija spoja 2 s heksakloracetonom u diklormetanu koji je dodan s trifenilfosfinom pri temperaturi od 0-5 °C, a zatim zagrijavanje do 10-15 °C, pri čemu nastaje 7a-klor-5,6B-epoksi-15B,16B-metilen-3B-pivaloiloksi-5B-androstan-17-on 3:
Z means oxygen atom, or -NR12- group - where R12 stands for hydrogen atom, methyl group, benzyl group or acetyl group; 
Z označuje atom kisika ili -NR12- skupinu, gdje R12 predstavlja atom vodika, metilnu skupinu, benzilnu skupinu ili acetilnu skupinu;
With the control levers in the neutral position, the user begins unmooring from the dock by going to the stem of the boat and releasing the lines holding the boat to the dock. 
Uz upravljačke kontrole u neutralnom položaju, korisnik započinje odvezivanje plovila tako da odlazi na krmu plovila i otpušta veze koje pridržavaju plovilo vezano uz pristanište.
The main goal is to replace those food ingredients that are used in the largest quantities, but at the same time present an insidious poison to - even healthy - human beings. 
Glavni je cilj zamijeniti one sastojke hrane koji se koriste u velikim količinama, a istodobno su prikriveni otrov čak i za zdravo ljudsko biće.
Suitable anions include chloride, bromide, iodide, sulfate, bisulfate, sulfamate, nitrate, phosphate, citrate, methanesulfonate, trifluoroacetate, glutamate, glucuronate, glutarate, malate, maleate, succinate, fumarate, tartrate, tosylate, salicylate, lactate, naphthalenesulfonate, and acetate. 
Spoj prema bilo kojem od prethodnih Zahtjeva 1 do 3, naznačen time, što spomenuta sol predstavlja klorid, bromid, jodid, sulfat, bisulfat, sulfamat, nitrat, fosfat, citrat, metansulfonat, trifluoroacetat, glutamat, glukuronat, glutarat, malat, maleat, sukcinat, fumarat, tartrat, tozilat, salicilat, laktat, naftalinesulfonat ili acetat.
Sugar binds water in the food, enhances the flavour and counteracts the harshness of salt. 
Šećer u prehrambenom proizvodu veže vodu, poboljšava okus i ublažava oštrinu dodane soli.
The chimeric human/rodent MHC II polypeptide of any one of claims 11-13, wherein the rodent is a mouse, and wherein the human MHC II a polypeptide is selected from the group consisting of HLA-DR a polypeptide, HLA-DQ a polypeptide and HLA-DP a polypeptide, and the rodent MHC II a polypeptide is an H-2E a polypeptide; or wherein the human MHC II B polypeptide is selected from the group consisting of HLA-DR B polypeptide, HLA-DQ B polypeptide and HLA-DP B polypeptide, and the rodent MHC II B polypeptide is an H-2E B polypeptide. 
Kimerni ljudski/glodarski MHC II-polipeptid prema bilo kojem od patentnih zahtjeva 11 do 13, naznačen time, da glodavac je miš, i pritom je ljudski MHC II-a-polipeptid odabran iz skupine koja se sastoji od HLA-DR-a-polipeptida, HLA-DQ-a-polipeptida i HLA-DP-a-polipeptida, i glodarski MHC II-a-polipeptid je H-2E-a-polipeptid; ili time, da je ljudski MHC II-B-polipeptid odabran iz skupine koja se sastoji od HLA-DR-B-polipeptida, HLA-DQ-B-polipeptida i HLA-DP-B-polipeptida, dok je glodarski MHC II-B-polipeptid jedan H-2E-B-polipeptid.
A pharmaceutical composition comprising a compound of any of items 1-47, or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable carrier, diluent or excipient. 
Farmaceutski pripravak, naznačen time, da sadržava spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili njegov stereoizomer ili njegovu farmaceutski prihvatljivu sol, 1 farmaceutski prihvatljiv nosač, razrjeđivač ili ekscipijens.
and pharmaceutically acceptable enantiomers, diastereomers, racemates, and salts thereof. Also disclosed is a compound of Formula (Ia) wherein: R1 
R> dušikom na koji su oba spojeni da oblikuju pet do sedam člani monociklički prsten; i njihovi farmaceutski prihvatljivi enantiomeri, diastereomeri, racemati i soli.
A bispecific single chain antibody comprising a first binding domain capable of binding to an epitope of CD3 epsilon (CD3e) of human and non-chimpanzee primate, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 
Bispecifično jednolančano protutijelo, naznačeno time što sadrži prva vežuća domena, koja se može vezati na epitop CD3 epsilon (CD3g) kod čovjeka i primata koji nije čimpanza, gdje je epitop dio aminokiselinskog slijeda koji pripada skupini koju čine SEQ ID NO.
The chimeric human/non-human animal MHC I polypeptide of claim 13 or 14, wherein the human HLA class I polypeptide is a human HLA-A polypeptide (such as a HLA-A2 polypeptide, e.g. a HLA-A2.1 polypeptide) and the non-human animal MHC I polypeptide is a mouse H-2K polypeptide (such as a H-2Kb polypeptide). 
Kimerni ljudski/ne-ljudski, životinjski MHC-I-polipeptid prema zahtjevu 13 ili 14, naznačen time, da ljudski polipeptid HLA-razreda I je ljudski HLA-A-polipeptid (kao što je HLA-A2-polipeptid, primjerice HLA-A2.1- polipeptid) i ne-ljudski, životinjski MHC-I-polipetid je mišji H-2K-polipeptid (kao što je primjerice H-2Kb- polipeptid).
The composition for the use of claim 13, wherein the second cytomegalovirus vector encodes an active UL128 protein and an active UL130 protein. 
Pripravak za uporabu u skladu s patentnim zahtjevom13, naznačen time, da drugi vektor citomegalovirusa kodira aktivni protein UL128 i aktivni UL130 protein.
A compound of Formula 1, a tautomer thereof or a pharmaceutically acceptable salt of the compound or tautomer, wherein: 
Spoj s formulom 1, [image] njegov tautomer ili farmaceutski prihvatljiva sol spoja ili tautomer, pri čemu:
Process for packing products based on portions of fish in the solid form, characterized in that it comprises at least: 
PATENTNI ZAHTJEVI Postupak pakiranja proizvoda koji se temelje na porcijama ribe u čvrstom obliku, naznačen time što obuhvaća barem:
The method of clause 42, wherein the cognitive disorders and diseases are selected from the group consisting of Alzheimer's Disease, forms of memory loss, and age-dependent memory loss. 
Spoj prema patentnom zahtjevu 11, naznačen time što su kognitivni poremećaji 1 bolesti izabrani iz grupe koju čine Alzhajmerova bolest, oblici gubitka pamćenja i gubitak pamćenja ovisan od starenja.
33A, modifying the angle between the first angular edge 4534 and the longitudinal axis of the post 4522 can affect the force required to insert the post 4522 into a split ring, for example the split ring schematically depicted in FIGS. 
Sustav za bravljenje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što potporanj dodatno sadrži zaobljeni dio, koji se nalazi između prvog ruba kuta i drugog ruba kuta.
The injector of claim 1, further comprising a mechanical, electro-mechanical, or electrical input device coupled to the actuator. 
Ubrizgač prema bilo kojem od prethodnih zahtjeva, koji dodatno sadrži mehanički ili električni ulazni uređaj spojen s pokretačem (456).
The imaging material supply cartridge (24) of claim 1 further comprising an imaging material in the body (34), wherein the imaging material comprises ink. 
Spremišna patrona za materijal za pisanje (24) u skladu s patentnim zahtjevom 1, naznačena time što u tijelu (34) dodatno sadrži materijal za pisanje, gdje materijal za pisanje sadrži tintu.
A compound according to Claim 1 or Claim 2 that is: or a pharmaceutically acceptable salt thereof. 
Spoj prema patentnim zahtjevima 1 ili 2 gdje R8 je halogen, NR11R12, N(R11)OR11, NR11NR11R12, OR11 ili SR11.
The tire vulcanizer according to claim 1, wherein a plurality of the squeezing cylinder mechanisms are arranged. 
Uređaj za vulkanizaciju gume u skladu s patentnim zahtjevom 1, naznačen time, da postoji veći broj mehanizama kompresijskog cilindra (20).
The mixture obtained was diluted with 1.5 l methanol and the NaCl precipitate was removed by filtration. 
Dobivena smjesa se Tazrijedi s 1,5 1 metanola i NaCl precipitat se odstrani filtracijom.
The nanoparticles according to anyone of claims 1 to 13, wherein the cancer is a solid tumor or a hematopoietic tumor, preferably selected from the group consisting of hepatocellular carcinoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, chronic myelogenous leukemia, Hodgkin's disease, diffuse large B-cell lymphoma, small cell lung cancer, colorectal cancer, pancreas cancer, breast cancer, ovary cancer, uterine cancer, cervix cancer, head and neck cancer, brain cancer, blade cancer, multiple myeloma, neuroblastoma, Edwing's sarcoma, osteosarcoma, soft tissue sarcoma, thyroid cancer, prostate cancer, stomach cancer, nephroblastoma, Kaposi's sarcoma, and non-Hodgkins lymphoma. 
Nanočestice za uporabu prema bilo kojem od zahtjeva 1-8, naznačene time da karcinom je solidni tumor ili hematopoetski tumor, poželjno odabran iz skupine koja sadrži hepatocelularni karcinom, akutnu limfoblastičnu leukemiju, akutnu mijeloičnu leukemiju, kroničnu mijelogenu leukemiju, Hodgkinsovu bolest, difuzni B- velikostanični limfom, rak pluća malih stanica, rak debelog crijeva, rak gušterače, rak dojke, rak jajnika, rak maternice, rak grlića maternice, rak glave i vrata, rak mozga, rak mjehura, multipli mijelom, neuroblastom, Ewingov sarkom, osteosarkom, sarkom mekog tkiva, rak štitnjače, rak prostate, rak želuca, nefroblastom, Kapozijev sarkom, te ne-Hodgkinov limfom.
According to a preferred aspect, the lipophilic extract of Zingiber officinale and the lipophilic extract of Echinacea angustifolia will be formulated in vegetable oils rich in w3/w6 polyunsaturated fatty acids, such as evening primrose oil. 
Pripravak kako je naveden u patentnim zahtjevima 1 12, naznačen time da su mase dviju komponenata sljedeće: a) lipofilni ekstrakt Zingiber officinale: 12.5 mg, te b) lipofilni ekstrakt Echinacea angustifolia: 5 mg.
A method of paragraph 28, wherein the disorder or disease is lung disease. A method of paragraph 28, wherein the disorder or disease is a genetic disease caused by mutations in Wnt signaling components, wherein the genetic disease is selected from: polyposis coli, osteoporosis-pseudoglioma syndrome, familial exudative vitreoretinopathy, retinal angiogenesis, early coronary disease, tetra-amelia syndrome, Müllerian-duct regression and virilization, SERKAL syndrome, diabetes mellitus type 2, Fuhrmann syndrome, Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome, odonto-onycho-dermal dysplasia, obesity, split-hand/foot malformation, caudal duplication syndrome, tooth agenesis, Wilms tumor, skeletal dysplasia, focal dermal hypoplasia, autosomal recessive anonychia, neural tube defects, alpha-thalassemia (ATRX) syndrome, fragile X syndrome, ICF syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann Syndrome and Rett syndrome. 
Spoj prema zahtjevu 1, ili njegova farmaceutski prihvatljiva sol, naznačen time da je za upotrebu za liječenje genetske bolesti uzrokovane mutacijama u Wnt signalnim komponentama, pri čemu je genetska bolest odabrana iz skupa koji čine: polipoza coli, osteoporoza-pseudoglioma sindrom, obiteljska eksudativna vitreoretinopatija, retinalna angiogeneza, rana koronarna bolest, sindrom tetra-amelia, regresija i virilizacija Miillerovih kanala, SERKAL sindrom, dijabetes melitus tipa 2, Fuhrmannov sindrom, Al-Awadi/Raas-Rothschild/Schinzelov fokomelija sindrom, odonto-oniho-dermalna displazija, pretilost, malformacija razdvojena ruka/stopalo, sindrom kaudalnog dupliciranja, ageneza zuba, Wilmsov tumor, skeletna displazija, fokalna dermalna hipoplazija, autosomna recesivna anonihija, defekti neuralne cijevi, alfa-talasemija (ATRX) sindrom, sindrom lomljivog kromosoma X, ICF sindrom, Angelmanov sindrom, Prader-Willijev sindrom, Beckwith-Wiedemannov sindrom i Rettov sindrom.
The compound or composition for use according to claim 1, wherein the disease or disorder is hematologic cancer. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da bolest ili poremećaj je rak jetre.
The method of claim 22, wherein the antibody or antigen-binding fragment is administered intravenously. 
izoliranje anti-beta-amiloidnog protutijela ili njegovog fragmenta koji veže antigen iz stanične kulture.
A process according to claim 19 characterised in that the heating of the elastomer material of the closure adjacent the puncture site so that the material fuses is done by directing laser light onto the elastomer material adjacent the puncture site. 
Postupak u skladu s patentnim zahtjevom 19, naznačen time, što se zagrijavanje elastomernog materijala zatvarača na mjestu uz probod obavlja tako da se materijal topi zbog usmjeravanja laserskog svijetla na elastomerni materijal koji se nalazi uz mjesto proboda.
The mechanism (1) according to claim 1, wherein the first and second axes (A 1; A 2) of the first and second cog wheels (12; 22) are horizontal, and the reference plane (P 0) is vertical. 
Mehanizam (1) prema jednom od zahtjeva od 1 do 3 naznačen time što su osovine (Al, A2) zupčanika (12, 22) vodoravne, a referentna razina (PO) okomita.
In one embodiment of the invention, the bisphosphonate is selected from the group consisting of risedronate, alendronate, pamidronate, tiludronate, cimadronate, ibandronate, clodronate, zoledronate, and salts, esters, hydrates, hemihydrates, polymorphs, and solvates thereof, and combinations thereof. 
PATENTNI ZAHTJEVI L Oralni oblik za doziranje farmaceutskog sastojka koji sadrži: a) bisfosfonat odabran iz rizedronata i soli, estera, hidrata, hemihidrata, polimorfa, i solvata istih, i kombinacija istih; b) od 75 mg do 250 mg dinatrijeve EDTA: i
A combination as claimed in claim 18, or a combination for use as claimed in claim 19, wherein an anti avB6 antibody is the other pharmaceutically active agent. 
Kombinacija u skladu s patentnim zahtjevom 18, ili kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 19, naznačena time što je protutijelo protiv avB6 drugo farmaceutski aktivno sredstvo.
In those cases, the composition of the beverage or foodstuff will need to be optimised to achieve sufficient stability against light induced flavour changes. 
U tim slučajevima, pripravak pića ili prehrambenog proizvoda je potrebno optimizirati da se postigne dovoljna stabilnost s obzirom na promjene arome inducirane svjetlom.
A compound of formula II: wherein 
Spoj sa formulom II: naznačen time da
Process for cleaning and sanitizing surgical tools or surgical instruments in general, comprising the use of abrasive cleaning material, emitted under pressure and at high speed against said instruments for abrading and removing the substances that adhere to the surfaces of the same instruments, characterized in that said abrasive cleaning material comprises sodium bicarbonate salts, mixtures of the same. 
HR P20150714 T1 PATENTNI ZAHTJEVI Postupak čišćenja 1 dezinfekcije (sanitarni postupak) kirurških alata ili kirurških instrumenata općenito, obuhvaća uporabu abrazivnog materijala za čišćenje, ispuštenog pod pritiskom i velikom brzinom na te instrumente radi struganja i uklanjanja tvari koje su se primile za površine tih istih instrumenata, naznačen time što taj abrazivni materijal za čišćenje sadrži soli natrijevog bikarbonata i njihove mješavine.
The print medium of claim 4, wherein the pigment has a specific surface area of greater than 25 m2/g, preferably from 25 to 100 m2/g or from 30 to 50 m2/g. 
Tiskovna podloga prema zahtjevu 3, pri čemu pigment ima specifičnu površinu veću od 25 m2/g, poželjno od 25 do 100 m2/g ili od 30 do 50 m2/g.
Pharmaceutical composition of claim 12 for use in treating neuropathic pain, osteoarthritis, rheumatoid arthritis, fibromyalgia, and back, musculoskeletal pain, ankylosing spondylitis, juvenile rheumatoid arthritis, diabetic neuropathy, migraines, dental pain, abdominal pains, ischemic pain, postoperative pain or because of an anesthetic or surgical contrition. 
Farmaceutski pripravak prema zahtjevu 12 za upotrebu u liječenju neuropatske boli, osteoartritisa, reumatoidnog artritisa, fibromijalgije, boli leđa, mišićno-kosturne boli, ankilozantnog spondilitisa, juvenilnog reumatoidnog artritisa, dijabetske neuropatije, migrena, dentalne boli, abdominalne boli, iskemijske boli, postoperativne boli ili zbog ancstetičke ili kirurške ozljede.